Can Mini-Dose Glucagon Prevent Fasting-Induced Hypoglycemia and Preserve Fasting?

Individuals with diabetes, particularly those using insulin, face substantial challenges when fasting during the Islamic month of Ramadan due to prolonged periods without food or drink and an increased risk of hypoglycemia. Mini-dose glucagon (MDG) has been considered as an alternative to oral carbohydrate intake for mild or impending hypoglycemia without breaking the fast; however, current evidence is limited and remains preliminary, derived largely from small pilot studies and limited real-world data.  This hypothesis-generating review synthesizes findings from a pilot RCT (n=17), an observational survey (n=136), and a focused literature search, providing the reader with the best evidence so far on this topic. Across the available evidence, MDG appears feasible for short-term correction of mild hypoglycemia, yet its efficacy, safety, and optimal dosing during fasting remain insufficiently established. Limitations of the present studies, such as small sample sizes, investigators' involvement, and heterogeneity in study designs, suggest cautious interpretation.  Considering the relatively early nature of the evidence and the importance of patient safety at fasting times, the use of MDG cannot be regarded as a proven or routine strategy. Larger, independently conducted studies are required to clarify its clinical role, validate dosing protocols, and ensure alignment with safety-first recommendations for fasting individuals with diabetes.